SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
ViroPharma Incorporated and Halozyme Therapeutics, Inc. Announce Initiation of Phase 2b Dose Ranging Combination Study for Subcutaneous Administration of Cinryze® (C1 Esterase Inhibitor [Human]) With Hyaluronidase (rHuPH20)